Study characteristics for pharmacological interventions.

Note.
* Data not reported in sufficient detail to include in analysis
1 Molindone was the third arm of this trial (n = 40), however as it was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010, only data for risperidone and olanzapine are used in this review
2 The study design consisted of an 8 week ‘acute phase’ and a blind ‘maintenance phase’ up to 52 weeks post randomization. During the maintenance phase participants continued to be administered treatment within their randomised groups and at same dose range.
3 Loxapine was the third arm of this trial (n = 26), however it was not included in this guideline as it was discontinued in the UK in 2003.
4This trial included a fourth arm of paliperidone 6–12mg/day. The 3–6mg/day arm was selected as the ‘higher dose’ antipsychotic medication in accordance with POMH-UK Topic 10 benchmarking exercise and therefore the 6–12mg/day arm was not included in the current work.
N = number randomised; nr = not reported; na = not applicable; mg = milligrams; DU = duration of treatment; PT = post-treatment data collection; FU = follow-up data collection
Study characteristics for pharmacological interventions.